Use of Ampicillin/Sulbactam Versus Imipenem/Cilastatin in the Treatment of Limb-Threatening Foot Infections in Diabetic Patients
1994
In a double-blind randomized trial, imipenem/cilastatin (I/C; 500 mg every 6 hours) and ampicillin/sulbactam (A/S; 3 g every 6 hours) were compared in regard to their efficacy for initial empirical and definitive parenteral treatment of limb-threatening pedal infection in diabetic patients. The major endpoints of treatment were cure (resolution of soft-tissue infection), failure (inadequate improvement, necessitating a change in antibiotic therapy), and eradication (clearance of all pathogens from the wound and any bone cultures)
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
20
References
173
Citations
NaN
KQI